OMER

Company Overview — What Does OMEROS CORP Do?

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. OMEROS CORP (OMER) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gregory A. Demopulos and employs approximately 210 people, headquartered in Seattle, Washington. With a market capitalization of $856M, OMER is one of the notable companies in the Healthcare sector.

OMEROS CORP (OMER) Stock Rating — Reduce (April 2026)

As of April 2026, OMEROS CORP receives a Reduce rating with a composite score of 32.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OMER ranks #2,700 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, OMEROS CORP ranks #365 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OMER Stock Price and 52-Week Range

OMEROS CORP (OMER) currently trades at $11.56. The stock lost $0.35 (2.9%) in the most recent trading session. The 52-week high for OMER is $17.65, which means the stock is currently trading -34.5% from its annual peak. The 52-week low is $2.95, putting the stock 291.9% above its annual trough. Recent trading volume was 970K shares, suggesting relatively thin trading activity.

Is OMER Overvalued or Undervalued? — Valuation Analysis

OMEROS CORP (OMER) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, OMEROS CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

OMEROS CORP Profitability — ROE, Margins, and Quality Score

OMEROS CORP (OMER) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 58.9%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -37.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OMER Debt, Balance Sheet, and Financial Health

OMEROS CORP has a debt-to-equity ratio of -84.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.76x, indicating strong short-term liquidity. Total debt on the balance sheet is $88M. Cash and equivalents stand at $2M.

OMER has a beta of 1.13, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for OMEROS CORP is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

OMEROS CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, OMEROS CORP reported revenue of $0 and earnings per share (EPS) of $-0.05. Net income for the quarter was $-122M. Operating income came in at $-129M.

In FY 2025, OMEROS CORP reported revenue of $0 and earnings per share (EPS) of $-0.05. Net income for the quarter was $-3M. Operating income came in at $-123M.

In Q3 2025, OMEROS CORP reported revenue of $0 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-31M. Operating income came in at $-26M.

In Q2 2025, OMEROS CORP reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-25M. Operating income came in at $-32M.

Over the past 8 quarters, OMEROS CORP has experienced revenue contraction from $0 to $0. Investors analyzing OMER stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OMER Dividend Yield and Income Analysis

OMEROS CORP (OMER) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OMER Momentum and Technical Analysis Profile

OMEROS CORP (OMER) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

OMER vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, OMEROS CORP (OMER) ranks #365 out of 838 stocks based on the Blank Capital composite score. This places OMER in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OMER against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OMER vs S&P 500 (SPY) comparison to assess how OMEROS CORP stacks up against the broader market across all factor dimensions.

OMER Next Earnings Date

No upcoming earnings date has been announced for OMEROS CORP (OMER) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OMER? — Investment Thesis Summary

The quantitative profile for OMEROS CORP suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. High volatility (stability score 20/100) increases portfolio risk.

In summary, OMEROS CORP (OMER) earns a Reduce rating with a composite score of 32.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OMER stock.

Related Resources for OMER Investors

Explore more research and tools: OMER vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OMER head-to-head with peers: OMER vs AZN, OMER vs SLGL, OMER vs VMD.